V. Bürger

P.3.026 Fixed doses of escitalopram and paroxetine for the treatment of social anxiety disorder (SAD)

M. Lader, R. Nil, K. Stender, 2003, European Neuropsychopharmacology.

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study

W. Poewe, O. Rascol, W. Meissner, 2021, Journal of Parkinson's disease.

Efficacy and tolerability of escitalopram in 12‐ and 24‐week treatment of social anxiety disorder: Randomised, double‐blind, placebo‐controlled, fixed‐dose study

M. Lader, R. Nil, K. Stender, 2004, Depression and anxiety.

Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE® AD02 in Patients with Early Alzheimer's Disease.

B. Dubois, J. Hort, A. Kurz, 2015, The journal of prevention of Alzheimer's disease.

Additional results from a phase ii study to assess the clinical and immunological activity, safety, and tolerability of affitope® ad02 in patients with early Alzheimer’s disease (AD)

B. Dubois, S. Hendrix, A. Schneeberger, 2015, Alzheimer's & Dementia.